[go: up one dir, main page]

WO2016014992A3 - Compositions for treatment, diagnosis and prognosis of diseases - Google Patents

Compositions for treatment, diagnosis and prognosis of diseases Download PDF

Info

Publication number
WO2016014992A3
WO2016014992A3 PCT/US2015/042084 US2015042084W WO2016014992A3 WO 2016014992 A3 WO2016014992 A3 WO 2016014992A3 US 2015042084 W US2015042084 W US 2015042084W WO 2016014992 A3 WO2016014992 A3 WO 2016014992A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
treatment
prognosis
diseases
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/042084
Other languages
French (fr)
Other versions
WO2016014992A2 (en
Inventor
Jenny L. PERSSON
Heather H. JOHNSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Everest Biosciences Inc
Original Assignee
Everest Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Everest Biosciences Inc filed Critical Everest Biosciences Inc
Publication of WO2016014992A2 publication Critical patent/WO2016014992A2/en
Publication of WO2016014992A3 publication Critical patent/WO2016014992A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01068—1-Phosphatidylinositol-4-phosphate 5-kinase (2.7.1.68)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed herein are novel pharmaceutically-useful compositions comprising an inhibitor of PIP5KIA, which compositions may be useful in the treatment of diseases such as cancer. Also disclosed is the use of the compositions for disease diagnosis and prognosis, treatment selection and disease progression monitoring.
PCT/US2015/042084 2014-07-24 2015-07-24 Compositions for treatment, diagnosis and prognosis of diseases Ceased WO2016014992A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462028783P 2014-07-24 2014-07-24
US62/028,783 2014-07-24

Publications (2)

Publication Number Publication Date
WO2016014992A2 WO2016014992A2 (en) 2016-01-28
WO2016014992A3 true WO2016014992A3 (en) 2016-03-17

Family

ID=55163985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/042084 Ceased WO2016014992A2 (en) 2014-07-24 2015-07-24 Compositions for treatment, diagnosis and prognosis of diseases

Country Status (1)

Country Link
WO (1) WO2016014992A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106544361A (en) * 2016-12-02 2017-03-29 新乡医学院 Mammalian cell expression vector, expression system, preparation method and application

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12096031B2 (en) 2017-06-05 2024-09-17 Immersive Robotics Pty Ltd. Method and apparatus for digital content stream compression and decompression

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114400A1 (en) * 2001-12-06 2003-06-19 Isis Pharmaceuticals Inc. Antisense modulation of phosphatidylinositol-4-phosphate 5-kinase, Ialpha expression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114400A1 (en) * 2001-12-06 2003-06-19 Isis Pharmaceuticals Inc. Antisense modulation of phosphatidylinositol-4-phosphate 5-kinase, Ialpha expression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LI ET AL.: "The ATM Inhibitor KU-55933 Suppresses Cell Proliferation and Induces Apoptosis by Blocking Akt In Cancer Cells with Overactivated Akt.", MOL CANCER THER, vol. 9, no. 1, January 2010 (2010-01-01), pages 113 - 125 *
MUSCOLINI ET AL.: "Phosphatidylinositol 4-Phosphate 5-Kinase alpha Activation Critically Contributes to CD 28-Dependent Signaling Responses.", THE JOURNAL OF IMMUNOLOGY, vol. 190, no. 10, 15 May 2013 (2013-05-15), pages 5279 - 5286 *
VAN DEN BOUT ET AL.: "PIP5K-driven Ptdlns(4,5)P2 synthesis: regulation and cellular function.", J CELL SCI, vol. 122, no. 21, 1 November 2009 (2009-11-01), pages 3837 - 3850 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106544361A (en) * 2016-12-02 2017-03-29 新乡医学院 Mammalian cell expression vector, expression system, preparation method and application

Also Published As

Publication number Publication date
WO2016014992A2 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
IL264049A (en) Compounds, compositions, and methods for the treatment of disease
WO2017030823A3 (en) Anti-tigit antibodies
EP3448874A4 (en) Compositions for the treatment of disease
EP3448987A4 (en) Compositions for the treatment of disease
EP3675859A4 (en) Compounds, compositions, and methods for the treatment of disease
MD4733B1 (en) Anti-TIGIT antibodies
IL264156A (en) Compounds, compositions, and methods for the treatment of disease
WO2016100985A3 (en) Chimeric antigen receptors and methods of use thereof
EP3177732A4 (en) Compositions and methods for the treatment of ophthalmic diseases and conditions
WO2015148863A3 (en) Crispr/cas-related methods and compositions for treating sickle cell disease
WO2016098079A3 (en) Compositions and methods for antibodies targeting bmp6
MX2017009417A (en) Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof.
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
CN106659716A8 (en) Apilimod compositions and methods of use thereof
WO2015179835A3 (en) Mit biomarkers and methods using the same
WO2016106343A8 (en) Probiotic organisms for diagnosis, monitoring, and treatment of inflammatory bowel disease
EP3149192A4 (en) Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers
WO2015120372A3 (en) Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases
WO2016138538A3 (en) Therapeutic use of integrin-binding antibodies
WO2016094374A8 (en) Compositions and methods for treatment of friedreich's ataxia
WO2015179823A3 (en) Lung localized inhibitors of alpha(v)beta 6
MX382092B (en) Heterocyclic compounds for the treatment of disease
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
WO2016014992A3 (en) Compositions for treatment, diagnosis and prognosis of diseases
WO2015013233A3 (en) Methods and compositions for the treatment and diagnosis of bladder cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15824903

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15824903

Country of ref document: EP

Kind code of ref document: A2